Boston Scientific’s Nalu And Penumbra Bets Reframe Growth And Valuation Profile

• Boston Scientific (NYSE:BSX) recently completed its acquisition of Nalu Medical, expanding its presence in pain management devices.
• The company has also announced a pending US$14.5b deal to acquire Penumbra, which would extend its reach into neurovascular therapies.
• Together, these moves mark a shift in Boston Scientific’s portfolio mix toward large, high-growth medical technology segments.

Boston Scientific is already a major player in cardiovascular and other interventional medical devices, and Nalu Medical adds a foothold in peripheral nerve stimulation for chronic pain. The proposed Penumbra transaction would broaden exposure to neurovascular and related therapies, areas that many medical technology companies view as important for long-term demand. For investors, these moves change the profile of NYSE:BSX compared with its more established product lines.

What matters now is how quickly and effectively Boston Scientific integrates Nalu Medical and, if completed, Penumbra into its broader platform. Execution around product development, regulatory milestones, and commercial rollout will shape how these deals influence margins, cash flow, and the company’s position against other large-device manufacturers over the coming years.

Stay updated on the most important news stories for Boston Scientific by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Boston Scientific.

Why Boston Scientific could be great value

Investor Checklist

Quick Assessment

• ✅ Price vs Analyst Target: At US$93.53, the share price sits about 25% below the US$124.41 analyst target.
• ❌ Simply Wall St Valuation: Shares are flagged as trading 35.9% above estimated fair value.
• ❌ Recent Momentum: The stock has returned about 1.9% over the last 30 days.

Check out Simply Wall St’s
in depth valuation analysis for Boston Scientific.

Key Considerations

• 📊 The Nalu and Penumbra deals push Boston Scientific further into neurovascular and pain management, so your thesis may hinge more on these markets than its legacy lines.
• 📊 Keep an eye on integration progress, acquisition related costs, and any updates on regulatory approvals or product launches tied to these businesses.
• ⚠️ Simply Wall St flags one risk around debt levels, which is worth tracking as the company funds and absorbs these transactions.

Dig Deeper

For the full picture including more risks and rewards, check out the
complete Boston Scientific analysis.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com